SAG (Smoothened Agonist) HCl
SAG (Smoothened Agonist) HCl是一种细胞渗透性Smoothened (Smo)激动剂，其在Shh-LIGHT2细胞中的EC50约为3 nM。
SAG (Smoothened Agonist) HCl Chemical Structure
CAS: 2095432-58-7
产品质控
批次：
纯度：
99.98%
99.98
SAG (Smoothened Agonist) HCl相关产品
相关信号通路图
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| HUVEC | Cytotoxicity assay | 24 h | Cytotoxicity against HUVEC after 24 hrs by WST-1 assay, IC50=22 μM | 22985958 | |
| mouse Shh-Light II cell | Function assay | 48 hrs | Activation of Shh pathway in mouse Shh-Light II cells assessed as induction of gli1 expression after 48 hrs by renilla luminescence assay, EC50=0.0088 μM | 22985958 | |
| Shh-Light II | Function assay | 48 hrs | Activation of Shh pathway in mouse Shh-Light II cells assessed as induction of gli1 expression after 48 hrs by renilla luminescence assay, EC50 = 0.0618 μM. | 22985958 | |
| C3H10T1/2 | Function assay | 6 days | Agonist activity at Smo in mouse C3H10T1/2 cells assessed as induction of cell differentiation into osteoblast incubated for 6 days by alkaline phosphatase assay, EC50 = 0.13 μM. | 27429255 | |
| NIH/3T3 | Function assay | Agonist activity at Smo in mouse NIH/3T3 cells transfected with Gli-dependent firefly luciferase reporter assessed as stimulation of Gli transcription factor, EC50 = 0.03 μM. | 27429255 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | ||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | ||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | ||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | SAG (Smoothened Agonist) HCl是一种细胞渗透性Smoothened (Smo)激动剂，其在Shh-LIGHT2细胞中的EC50约为3 nM。 | ||
|---|---|---|---|
| 靶点 |
|
| 体外研究(In Vitro) | ||||
| 体外研究活性 | SAG通过直接结合到Smo螺旋束调控Smo活性。[1] SAG以GRK2依赖的方式诱导通过Gli的Smo-依赖性信号。[2] SAG(1 nM)也会诱导神经元和神经胶质前体细胞的增殖，而不影响新生细胞的分化模式。[3] |
|||
|---|---|---|---|---|
| 实验图片 | 检测方法 | 检测指标 | 实验图片 | PMID |
| Western blot | LC3I / LC3II |
|
23504944 | |
| Immunofluorescence | Smo acetylated alpha tubulin |
|
25636740 | |
| 体内研究(In Vivo) | ||
| 体内研究活性 | 在成年大鼠海马中，SAG (2.5 nM)脑室内给药显著增加新生细胞的数量，并延长海马细胞的存活时间。[3] 在小鼠中，SAG (20 μg/g, i.p.)有效防止GC-诱导的新生小脑发育异常。[4] |
|
|---|---|---|
| 动物实验 | Animal Models | 大鼠 |
| Dosages | 2.5 nM | |
| Administration | 侧脑室给药 | |
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05937178 | Recruiting | Hepatitis B Chronic |
Huashan Hospital|The First Affiliated Hospital of Anhui Medical University|Anhui Provincial Hospital|Beijing YouAn Hospital|Peking University People''s Hospital|Peking University First Hospital|Xiamen Hospital of Traditional Chinese Medicine|First Affiliated Hospital of Fujian Medical University|LanZhou University|Third Affiliated Hospital Sun Yat-Sen University|First Affiliated Hospital of Guangxi Medical University|The Affiliated Hospital Of Guizhou Medical University|Hainan General Hospital|Hebei Medical University Third Hospital|The First Affiliated Hospital of Henan University of Traditional Chinese Medicine|Henan Provincial People''s Hospital|The Second Affiliated Hospital of Harbin Medical University|Tongji Hospital|Wuhan Union Hospital China|Renmin Hospital of Wuhan University|Central South University|Xiangya Hospital of Central South University|The First Hospital of Jilin University|the Second Hospital of Nangjing|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|The First Affiliated Hospital with Nanjing Medical University|The Affiliated Hospital of Xuzhou Medical University|The First Affiliated Hospital of Nanchang University|Shengjing Hospital|Qingdao Sixth People''s Hospital|Shandong Provincial Hospital|The Second Hospital of Shandong University|The First Affiliated Hospital of Shanxi Medical University|Tang-Du Hospital|First Affiliated Hospital Xi''an Jiaotong University|Ruijin Hospital|West China Hospital|Tianjin Second People''s Hospital|First Affiliated Hospital of Xinjiang Medical University|The First People''s Hospital of Yunnan|Shulan (Hangzhou) Hospital|Zhejiang University|Southwest Hospital China|The Second Affiliated Hospital of Chongqing Medical University|Sichuan Provincial People''s Hospital |
January 31 2023 | -- |
| NCT05701592 | Recruiting | Posterior Cruciate Ligament Tear |
Konrad Malinowski MD|Artromedical Konrad Malinowski Clinic |
December 20 2022 | -- |
| NCT03645044 | Active not recruiting | Hiv|HBV Coinfection |
University of Melbourne|National Health and Medical Research Council Australia|The University of Western Australia|University of Adelaide|The HIV Netherlands Australia Thailand Research Collaboration|University of Malaya|YR Gaitonde Centre for AIDS Research and Education|Melbourne Health |
May 24 2018 | -- |
化学信息&溶解度
| 分子量 | 526.52 | 分子式 | C28H29Cl2N3OS |
| CAS号 | 2095432-58-7 | SDF | Download SAG (Smoothened Agonist) HCl SDF |
| Smiles | CNC1CCC(CC1)N(CC2=CC(=CC=C2)C3=CC=NC=C3)C(=O)C4=C(C5=CC=CC=C5S4)Cl.Cl | ||
| 储存条件(自收到货起) | |||
|
体外溶解度 |
DMSO : 82 mg/mL ( (155.73 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Water : 50 mg/mL (94.96 mM) Ethanol : 27 mg/mL (51.28 mM) |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
Tags: buy SAG (Smoothened Agonist) HCl | SAG (Smoothened Agonist) HCl supplier | purchase SAG (Smoothened Agonist) HCl | SAG (Smoothened Agonist) HCl cost | SAG (Smoothened Agonist) HCl manufacturer | order SAG (Smoothened Agonist) HCl | SAG (Smoothened Agonist) HCl distributor
